New drug trial targets rare blood disorder that makes patients sensitive to cold
NCT ID NCT06067048
Summary
This study is testing whether the drug zanubrutinib can help control cold agglutinin disease, a rare condition where the immune system attacks red blood cells, causing anemia and painful reactions to cold. The trial will enroll about 25 adults who have not responded well to other treatments. Researchers will see if taking zanubrutinib for six cycles improves blood counts and reduces cold-related symptoms.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AZ Delta
Roeselare, Belgium
-
Amsterdan UMC ( location AMC)
Amsterdam, Netherlands
-
Erasusmc
Rotterdam, Netherlands
-
Haukeland University Hospital Bergen
Bergen, Norway
-
Odense University Hospital
Odense, Denmark
-
Oslo University Hospital
Oslo, Norway
-
Rigshospitalet
Copenhagen, Denmark
-
UMCG
Groningen, Netherlands
-
UZ leuven
Leuven, Belgium
-
st. Olavs Hospital
Trondheim, Norway
Conditions
Explore the condition pages connected to this study.